Recent Research Analysts’ Ratings Changes for Adicet Bio (ACET)

A number of firms have modified their ratings and price targets on shares of Adicet Bio (NASDAQ: ACET) recently:

• 5/11/2026 – Adicet Bio was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/5/2026 – Adicet Bio is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $19.00 price target on the stock.
• 5/2/2026 – Adicet Bio was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 4/24/2026 – Adicet Bio was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 3/25/2026 – Adicet Bio was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/23/2026 – Adicet Bio had its price target lowered by HC Wainwright from $50.00 to $27.00. They now have a “buy” rating on the stock.

Insider Activity at Adicet Bio

In other Adicet Bio news, major shareholder Ra Capital Management, L.P. acquired 74,751 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were bought at an average cost of $7.27 per share, with a total value of $543,439.77. Following the completion of the transaction, the insider directly owned 1,182,624 shares of the company’s stock, valued at approximately $8,597,676.48. This represents a 6.75% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 223,596 shares of company stock worth $1,603,934 over the last 90 days. Company insiders own 3.40% of the company’s stock.

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.